Literature DB >> 22001709

Evaluation of a new standardized protocol for the perioperative management of chronically anticoagulated patients receiving implantable cardiac arrhythmia devices.

Oscar Cano1, Begoña Muñoz, David Tejada, Joaquín Osca, María-José Sancho-Tello, José Olagüe, José E Castro, Antonio Salvador.   

Abstract

BACKGROUND: Perioperative management of oral anticoagulation (OAC) in patients receiving pacemakers or implantable cardioverter-defibrillators remains an issue of concern.
OBJECTIVE: We sought to evaluate the safety and the effect on the hospital length of stay of a new standardized protocol for perioperative management of OAC in this setting.
METHODS: The new standardized protocol classified patients according to a renewed evaluation of their thromboembolic (TE) risk. Briefly, patients were considered at moderate-to-high TE risk if they had a mechanical valvular prostheses irrespective of type and location or atrial fibrillation associated with a CHADS(2)score of ≥2, mitral stenosis or previous stroke, and underwent device implantation without stopping OAC (OAC continued, n = 129). Complete interruption of OAC before surgery was performed in low-TE-risk patients (OAC interrupted, n = 82). A retrospective cohort of patients managed with a classic heparin-bridging strategy served as a control group, with 62 patients considered at moderate-to-high TE risk according to previous guidelines (receiving pre- and postoperative low-molecular-weight heparin) and 146 considered at low TE risk (receiving only low doses of postoperative low-molecular-weight heparin).
RESULTS: TE events were comparable between the 2 strategies. Patients entering the new standardized protocol had significantly lower rates of pocket hematoma (2.3% for OAC continued vs 17.7% for moderate-to-high TE risk bridging controls, P = .0001, and 0% for OAC interrupted vs 13% for low-TE-risk bridging controls, P <.0001) and shorter hospital stays. A mean of 3.34 hospitalization days per patient were saved with the new standardized protocol, with an estimated cost savings of €850.83 per patient.
CONCLUSIONS: Implantation of the new standardized protocol resulted in a significant reduction in bleeding complications and hospital stays, with adequate protection against TE events and significant cost savings. Copyright Â
© 2012 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22001709     DOI: 10.1016/j.hrthm.2011.10.010

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  8 in total

Review 1.  Perioperative management of antithrombotic therapy in patients receiving cardiovascular implantable electronic devices: a network meta-analysis.

Authors:  Hua He; Bing-Bing Ke; Yan Li; Fu-Sheng Han; Xiaodong Li; Yu-Jie Zeng
Journal:  J Interv Card Electrophysiol       Date:  2017-08-25       Impact factor: 1.900

Review 2.  How To Manage Oral Anticoagulation Periprocedurally During Ablations And Device Implantations.

Authors:  Sarah A Worsnick; Pugazhendhi Vijayaraman
Journal:  J Atr Fibrillation       Date:  2016-12-31

3.  Bleeding risk of submuscular ICD implantation with continued oral anticoagulation versus heparin bridging therapy.

Authors:  Simon Pecha; Ayhan Ayikli; Iris Wilke; Samer Hakmi; Yalin Yildirim; Nils Gosau; Hermann Reichenspurner; Stephan Willems; Muhammet Ali Aydin
Journal:  Heart Vessels       Date:  2017-10-13       Impact factor: 2.037

Review 4.  Safety of Anticoagulation Interruption in Patients Undergoing Surgery or Invasive Procedures: A Systematic Review and Meta-analyses of Randomized Controlled Trials and Non-randomized Studies.

Authors:  Frédérique Hovaguimian; Sabrina Köppel; Donat R Spahn
Journal:  World J Surg       Date:  2017-10       Impact factor: 3.352

Review 5.  Heart Rythm Society expert consensus statement on electrophysiology laboratory standards: process, protocols, equipment, personnel, and safety.

Authors:  David E Haines; Salwa Beheiry; Joseph G Akar; Janice L Baker; Doug Beinborn; John F Beshai; Neil Brysiewicz; Christine Chiu-Man; Kathryn K Collins; Matthew Dare; Kenneth Fetterly; John D Fisher; Richard Hongo; Samuel Irefin; John Lopez; John M Miller; James C Perry; David J Slotwiner; Gery F Tomassoni; Esther Weiss
Journal:  Heart Rhythm       Date:  2014-05-07       Impact factor: 6.343

Review 6.  Clinical considerations of anticoagulation therapy for patients with atrial fibrillation.

Authors:  Shu Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2012-08       Impact factor: 3.066

7.  Anticoagulation management of patients with long-term warfarin therapy after valve replacement during the perioperative period of pacemaker implantation.

Authors:  Zhi-Hong Han; Xue-Jun Ren; Ye Wang
Journal:  Int J Clin Exp Med       Date:  2013-08-01

8.  Periprocedural complications of cardiac implantable electronic device implantation in very elderly patients with cognitive impairment: A prospective study.

Authors:  Fu Guan; Jianjun Peng; Shu Hou; Lihui Ren; Yunan Yue; Guangping Li
Journal:  Medicine (Baltimore)       Date:  2021-11-19       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.